法国康复医学中周围运动神经阻滞临床指南
该指南由法国康复医学与麻醉重症学会组织18位专家制定,检索1999至2018年文献并分析355篇论文,未发现科学证据,推荐主要基于专家意见。指南涵盖8个问题:神经阻滞适应证、药物与禁忌、不良反应监测、注射与引导设备、患者准备与镇痛、疗效评估、患者信息、康复医师培训。关于药物剂量,利多卡因不超过2mg/kg、罗哌卡因不超过1.5mg/kg且最大100mg时,需核对禁忌、备好急救车,无需麻醉会诊或麻醉医师在场;罗哌卡因还需建立静脉通路。超过上述剂量需按SFAR指南并需麻醉医师参与。
要点
- 利多卡因剂量不超过2mg/kg时:核对禁忌证、备好急救车,无需事先麻醉会诊或麻醉医师在场。
- 罗哌卡因剂量不超过1.5mg/kg且最大100mg时:同利多卡因要求,但需先建立静脉通路。
- 超过上述剂量时须遵循SFAR指南,需要麻醉医师参与。
- 该指南为康复医学中运动神经阻滞的首个组织性指南,旨在提高安全性。
- 文献检索1999至2018年,分析355篇论文,未发现科学证据,推荐主要基于专家意见。
适用人群与场景
- 物理与康复医学(PRM)环境中接受运动神经阻滞的患者,尤其用于痉挛管理。
处置流程与药物剂量
- 利多卡因剂量不超过2mg/kg:核对禁忌证、备好急救车,无需事先麻醉会诊或麻醉医师在场。
- 罗哌卡因剂量不超过1.5mg/kg且最大100mg:核对禁忌证、备好急救车,需先建立静脉通路,无需事先麻醉会诊或麻醉医师在场。
- 超过利多卡因2mg/kg或罗哌卡因1.5mg/kg(最大100mg)时:遵循SFAR指南,需要麻醉医师参与。
研究设计与关键结果
- 制定机构:法国物理与康复医学学会(SOFMER)和法国麻醉与重症监护学会(SFAR)。
- 方法:18位专家经电子投票批准草案,最终由各学会科学委员会批准;检索Medline、Cochrane和Embase数据库1999至2018年文献,分析355篇论文。
- 结果:文献未发现科学证据,指南主要基于专家意见,涵盖8个问题。
证据类型、等级与局限
- 证据类型:临床指南(专家共识)。
- 证据等级:推荐主要基于专家意见,无科学证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在PRM环境中使用利多卡因不超过2mg/kg或罗哌卡因不超过1.5mg/kg(最大100mg)行运动神经阻滞时,可依据专家意见核对禁忌证、备好急救车,无需麻醉会诊或麻醉医师在场;罗哌卡因需先建立静脉通路。
- 超过上述剂量时,需按SFAR指南并请麻醉医师参与。
- 该指南为组织性指南,旨在提高运动神经阻滞在PRM环境中的安全性。
指南或共识出处
- French clinical guidelines for peripheral motor nerve blocks in a PRM setting(法国康复医学中周围运动神经阻滞临床指南),发布机构:法国物理与康复医学学会(SOFMER)和法国麻醉与重症监护学会(SFAR),年份未在原文中明确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Motor nerve blocks with anesthetic drug for local anesthesia are commonly used in physical and rehabilitation medicine (PRM), especially in the field of spasticity. Guidelines in this context are currently lacking.
METHOD: Eighteen experts selected on the basis of their recognized experience by the scientific committees of the French PRM (SOFMER) and Anesthesia and Intensive care (SFAR) societies were invited to work and propose guidelines for the use of loco-regional anesthetic drug for motor nerve blocks in PRM setting. Eight issues were addressed: which neural blocks for which indications; drugs and contraindications; medical survey and attitude in case of adverse event; injection and guidance material; patient preparation and pain relief; efficacy assessment; patient information; education of PRM physiatrists. The Medline, Cochrane and Embase databases for the period 1999 to 2018 were consulted and 355 papers analyzed. The drafts were commented then approved by the whole group using electronic vote, before final approval by scientific committee of each society.
RESULTS: No scientific evidence emerged from the literature. Thus, these guidelines are mainly based on the opinion of the expert panel. Guidelines for each issue are reported with the main points of arguments. The main question deals with the recommendation about doses for each drug: for lidocaine - up to 2mg/kg - "check contraindications, emergency truck available, no need of previous anesthetic consultation nor presence of anesthetic physician"; for ropivacaine - up to 1.5mg/kg, with a maximum of 100mg - the same but after intravenous line. Beyond these doses, SFAR guidelines have to be applied with the need of anesthetic physician.
CONCLUSION: These are the first organizational guidelines devoted to increase the security of motor nerve block use in PRM settings.
参考来源
- Yelnik AP, Hentzen C, Cuvillon P, et al. French clinical guidelines for peripheral motor nerve blocks in a PRM setting. Ann Phys Rehabil Med. 2019. PMID: 31202956. doi:10.1016/j.rehab.2019.06.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。